Look out Lucentis and Eylea: New radiotherapy for wet AMD threatens anti-VEGF – Clinica
This article was originally published in Scrip
Executive Summary
According to Clinica Medtech Intelligence, a non-invasive, one-time radiotherapy procedure developed by an emerging Californian company for treating wet age-related macular degeneration could threaten to stymie the double-digit growth that drug giants Novartis and Roche have seen in sales of their market-leading anti-VEGF therapy Lucentis.